🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Faldaprevir: 24-week treatment

Found 15 matching trials

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

PHASE2

The objective was to investigate the antiviral effect, safety, and pharmaco...

Status

Completed

Location

1220.5.0001 Boehringer Ingelheim Investigational Site

Start Date

2008-10

Trial ID

NCT00774397

Treatments Being Tested

BI 201335 NA 240 mg QD / LI PegIFN/RBV BI 201335 NA 120mg QD / LI PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg BID PegIFN/RBV PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV Placebo

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

PHASE3

The aim of this trial is to evaluate the safety and efficacy of BI 201335 g...

Status

Completed

Location

1220.54.08104 Boehringer Ingelheim Investigational Site

Start Date

2012-04

Trial ID

NCT01579474

Treatments Being Tested

BI 201335 high dose BI 201335 low dose BI 201335 high dose BI 201335 high dose

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

PHASE3

The aim of this trial is to evaluate efficacy and safety of treatment with ...

Status

Withdrawn

Location

1241.37.61002 Boehringer Ingelheim Investigational Site

Start Date

2013-05

Trial ID

NCT01858961

Treatments Being Tested

BI 201335 ribavirin BI 207127 Telaprevir ribavirin Pegylated Interferon

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

PHASE2

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120...

Status

Completed

Location

1241.30.10003 Boehringer Ingelheim Investigational Site

Start Date

2013-04

Trial ID

NCT01830127

Treatments Being Tested

Ribavirin BI 207127 high dose Faldaprevir Ribavirin BI 207127 low dose Faldaprevir

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

PHASE3

The aim of the study is to confirm efficacy of treatment for 16 and 24 week...

Status

Completed

Location

1241.20.00026 Boehringer Ingelheim Investigational Site

Start Date

2012-12

Trial ID

NCT01732796

Treatments Being Tested

Ribavirin (RBV)BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 Faldaprevir (BI 201335)BI 207127

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

PHASE3

The objective of this trial is to evaluate the efficacy and safety of two d...

Status

Completed

Location

1220.47.0004 Boehringer Ingelheim Investigational Site

Start Date

2011-04

Trial ID

NCT01297270

Treatments Being Tested

BI201335 PegIFN/RBV BI201335 Placebo

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

PHASE3

The objectives of this study are: 1. To evaluate the efficacy and safety o...

Status

Withdrawn

Location

Multiple Locations

Start Date

2012-09

Trial ID

NCT01608737

Treatments Being Tested

PegIFN/RBV BI 201335 BI 201335 PegIFN/RBV BI 201335

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

PHASE3

The aim of this trial is to evaluate the efficacy and the safety of BI 2013...

Status

Completed

Location

1220.7.0091 Boehringer Ingelheim Investigational Site

Start Date

2011-06

Trial ID

NCT01358864

Treatments Being Tested

BI 201335 Pegylated Interferon-alpha (IFN)Ribavirin (RBV)Placebo

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

PHASE1

To evaluate the drug-drug interactions between BI 201335 and BI 207127 as w...

Status

Completed

Location

1241.27.0006 Boehringer Ingelheim Investigational Site

Start Date

2012-04

Trial ID

NCT01525628

Previous Next